Erratum to: Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients

Deborah P. Saunders · Joel B. Epstein · Sharon Elad · Justin Allemano · Paolo Bossi · Marianne D. van de Wetering · Nikhil G. Rao · Carin Potting · Karis K. Cheng · Annette Freidank · Michael T. Brennan · Joanne Bowen · Kristopher Dennis · Rajesh V. Lalla · For The Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO)

Published online: 5 December 2014
© Springer-Verlag Berlin Heidelberg 2014

Erratum to: Support Care Cancer DOI 10.1007/s00520-013-1871-y

The original version of this paper unfortunately contains errors. Morphine 2 % rinse, should have read as Morphine 0.2 % rinse.

Page 3202, Paragraph 6

The online version of the original article can be found at <http://dx.doi.org/10.1007/s00520-013-1871-y>.

D. P. Saunders (✉) · J. Allemano
Department of Dental Oncology, North East Cancer Center, Health Sciences North, Sudbury, Ontario, Canada
e-mail: dsaunders@hsnsudbury.ca

J. B. Epstein
Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, Los Angeles, CA, USA

J. B. Epstein
City of Hope National Medical Center, Duarte, CA, USA

S. Elad
Division of Oral Medicine, Eastman Institute for Oral Medicine, University of Rochester Medical Center, Rochester, NY, USA

P. Bossi
Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

M. D. van de Wetering
Paediatric Oncology Department, Emma Children's Hospital, Academic Medical Centre, Amsterdam, The Netherlands

N. G. Rao
Department Radiation Oncology, Moffitt Cancer Center, Tampa, FL, USA

Two studies, including a RCT, examined the use of a 2 % morphine mouth rinse for the management of pain due to OM in patients receiving chemoradiation for H&N cancer [21, 22]. Where it should have read as:

Two studies, including a RCT, examined the use of a 0.2 % morphine mouth rinse for the management of pain due to OM in patients receiving chemoradiation for H&N cancer [21, 22].

C. Potting
Department of Haematology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

K. K. Cheng
Alice Lee Centre of Nursing Studies, National University of Singapore, Singapore, Singapore

A. Freidank
Department of Pharmacy, Klinikum Fulda gAG, Fulda, Germany

M. T. Brennan
Department of Oral Medicine, Carolinas Medical Center, Charlotte, NC, USA

J. Bowen
School of Medical Sciences, University of Adelaide, Adelaide, South Australia, Australia

K. Dennis
Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada

R. V. Lalla
Section of Oral Medicine and Neag Comprehensive Cancer Center, University of Connecticut Health Center, Farmington, CT, USA

Page 3202, Paragraph 7

The panel suggests that morphine 2 % mouth rinse can be effective for the management of pain due to OM in patients receiving chemoradiation for H&N cancer (level of evidence III).

Where it should have read as:

The panel suggests that morphine 0.2 % mouth rinse can be effective for the management of pain due to OM in patients receiving chemoradiation for H&N cancer (level of evidence III).

Page 3204, Paragraph 3

Although studies with such topical use of opioids were limited, the data did support a suggestion in favor of a 2 % morphine rinse in radiation-induced OM in H&N cancer patients.

Where it should have read as:

Although studies with such topical use of opioids were limited, the data did support a suggestion in favor of a 0.2 % morphine rinse in radiation-induced OM in H&N cancer patients.